New drug combo aims to tailor myeloma treatment to each patient
NCT ID NCT07624513
First seen Jun 10, 2026 · Last updated Jun 20, 2026 · Updated 3 times
Summary
This Phase 3 trial is testing a personalized approach for people with newly diagnosed multiple myeloma who are eligible for a stem cell transplant. After initial treatment with a four-drug combination (isatuximab, iberdomide, bortezomib, and dexamethasone), the next steps—consolidation and maintenance therapy—will be chosen based on each patient's risk profile and how well their cancer responds. The goal is to find the best treatment path for each individual, aiming for deeper and longer-lasting remission.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beth Israel Deaconess Medical Center (BIDMC)
Boston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
isatuximab, iberdomide, bortezomib, and dexamethasone
What this could lead to
If successful, this could lead to a more personalized treatment plan for multiple myeloma, potentially improving long-term disease control and reducing the chance of relapse.
What could go wrong
This is an early-stage Phase 3 trial, so results are not yet known. The combination of drugs may cause significant side effects, and the risk-adapted approach may not benefit all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.